Anaptysbio (ANAB) Net Cash Flow Growth (1y) (2017 - 2026)
Powered by 
Analysis
Anaptysbio (ANAB) Net Cash Flow Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 47.11% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 75.60% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | -100.75% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 149.49% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -104.22% |
| 10 | Anaptysbio | 1.62 Bn | 1.33 Bn | - | 142.03% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 142.03% |
| Dec 31, 2025 | 287.39% |
| Sep 30, 2025 | -45.28% |
| Jun 30, 2025 | -399.78% |
| Mar 31, 2025 | -237.86% |
| Dec 31, 2024 | -808.39% |
| Sep 30, 2024 | 1,443.96% |
| Jun 30, 2024 | 130.54% |
| Mar 31, 2024 | -23.76% |
| Dec 31, 2023 | -24.22% |
| Sep 30, 2023 | 32.26% |
| Jun 30, 2023 | 37.33% |
| Mar 31, 2023 | 107.06% |
| Dec 31, 2022 | -91.99% |
| Sep 30, 2022 | -422.88% |
| Jun 30, 2022 | -296.88% |
| Mar 31, 2022 | -1,077.43% |
| Dec 31, 2021 | 285.79% |
| Sep 30, 2021 | 133.90% |
| Jun 30, 2021 | -13.87% |